Kinetic methods were used to obtain regional estimates of benzodiazepine receptor concentration (Bmax) and equilibrium dissociation constant (Kd) from high and low specific activity (SA) [I1C]flumazenil ([I 1 C]
Ro 15-1788) positron emission tomography studies of five normal volunteers. The high and low SA data were simul taneously fit to linear and nonlinear three-compartment models, respectively. An additional inhibition study (pre treatment with 0.15 mg/kg of flumazenil) was perfo rmed on one of the volunteers, which resulted in an average gray matter Kllk2 estimate of 0.68 ± 0.08 mUml (linear three-compartment model, nine brain regions). The free fraction of flumazenil in plasma (fl) was determined for each study (high SA fl: 0.50 ± 0.03; low SA fl: 0.48 ± 0.05). The fr ee fraction in brain (f2) was calculated using the inhibition K/k2 ratio and each volunteer's mean fl value (f2 across volunteers = 0.72 ± 0.03 mllml) . Three methods (Methods I-III) were examined. Method I deter mined five kinetic parameters simultaneously [K I , k2, k3 ( = ko./2Bmax), k4, and ko./2/SA] with no a priori con straints. An average kon value of 0.030 ± 0.003 nM -I min -I was estimated for receptor-rich regions using Efforts to image central benzodiazepine (BZ) re ceptors using positron emission tomography (PET) began with the agonist e'C]flunitrazepam (Comar Method I. In Methods II and III , the ko./2/SA parameter was specifically constrained using the Method I value of kon and the volunteer's values Off2 and low SA (CillLmol) . Four parameters were determined simultaneously using Method II . In Method III, K/k2 was fixed to the inhibi tion value and only three parameters were estimated. Method I provided the most variable results and conver gence problems for regions with low receptor binding. Method II provided results that were less variable but very similar to the Method I results, without convergence problems . However, the K,lk2 ratios obtained by Method II ranged from 1.07 in the occipital cortex to 0.61 in the thalamus. Fixing the K,lk2 ratio in Method III provided a method that was physiologically consistent with the fixed value of f2 and resulted in parameters with considerably lower variability . The average Bmax values obtained using Method III were 100 ± 25 nM in the occipital cortex, 64 ± 18 nM in the cerebellum , and 38 ± 5.5 nM in the thal amus; the average Kd was 8.9 ± 1.0 nM (five brain re gions). Key Words: Benzodiazepine receptors e IC]Flumazenil-Human brain-Kinetic modeling Positron emission tomography . et aI., 1979, 1981) . Subsequently, the antagonist ["C]flumazenil (e'C]Ro 15-1788) Maziere et aI., 1983; Hantraye et aI., 1984 Hantraye et aI., , 1988 Persson et aI., 1985; Samson et aI., 1985; Shinotoh et aI., 1986 ) and the cyclopyrrolone ["C]suriclone (Frost et aI., 1986) were used. Of these ligands, ["C]flumazenil is superior for the PET imaging of BZ receptors due to its kinetic and pharmacological attributes and has been widely used for human studies.
PET studies of ["C]flumazenil binding have dem onstrated a rapid uptake and a high specific/ nonspecific ratio in human brain (Samson et aI., 1985; Shinotoh et aI., 1986) . The main metabolite of [ ll C]flumazenil has been shown to have a negligible contribution to the PET brain signal (Persson et ai. , 1989a) as a result of brain uptake. Flumazenil can be administered in large doses (Darragh et aI., 1983) , allowing PET studies at several specific ac tivities (SAs) to be performed. These characteris tics are advantageous for the quantification of BZ receptor binding parameters in vivo.
The quantification of e l C]flumazenil PET studies has included the measurement of receptor occu pancy after the administration of clonazepam (Shi notoh et aI., 1989) and CI 218,872 (de la Sayette et aI., 1991) . A linear two-compartment model has been used to quantify the kinetics of high SA [ ll C]flumazenil and regional transport rates, and ligand distribution volumes have been estimated (Koeppe et aI., 1991) . The distribution volumes re flect specific binding withstanding changes in ligand delivery (Holthoff et aI., 1991) .
However, the majority of the quantitative effort has been aimed at estimating BZ receptor concen tration (BmaJ and equilibrium dissociation constant (Kd) in vivo. Estimates of Bmax and Kd have been obtained for a variety of brain regions using pseu doequilibrium data acquired from multiple (Pappata et aI., 1988; Persson et aI., 1989b; Iyo et aI., 1991) and dual (Savic et aI., 1988; Blomqvist et aI., 1990; Abadie et aI., 1992) SA [ l 1 C]flumazenil PET stud ies. Pseudoequilibrium is assumed to exist when the ratio of the estimated free and bound ligand concen trations is constant over time and when changes in the bound concentration become small. In addition, Blomqvist et ai. (1990) estimated neocortical BZ re ceptor binding parameters using kinetic modeling.
In the above-referenced studies, the ligand was administered by bolus injection, which does not al low true equilibrium to be established during the time frame of the PET study. The majority of these studies used reference region data as the free ligand concentration. Therefore, these approaches relied on one or both of the following assumptions: (a) The pseudoequilibrium data accurately represented the true equilibrium data, and (b) nonspecific binding was negligible.
The primary goal of this work was to use kinetic methods to obtain regional estimates of human BZ receptor Bmax and Kd from high and low SA e l C]flumazenil PET data acquired after bolus injec tion of ligand. Linear and nonlinear three compartment models were simultaneously fit to the regional data with and without the use of reference region data while accounting for nonspecific bind ing.
METHODS

Chemistry
HPLC purifications and analyses were performed on a previously described system (Dannals et aI. , 1986) . The HPLC columns used were either (A) Alltech Econosil C18 (250 mm x 10 mm) or (B) Alltech Econosil C18 (250 mm x 4.6 mm). Peak areas were measured using Hewlett Packard 3390A recording integrators. Isolated radio chemical yields were determined with a Capintec CRC-5R dose calibrator.
e 1C]Iodomethane was prepared as described previ ously (Dannals et aI. , 1990) and trapped in a solution of Ro 15-5528 (1 mg) in dimethyl-formamide (DMF) (200 fL1) at -70°C. Tetrabutylammonium hydroxide (10 fLl of a 0.4 M aqueous solution) was added and the reaction mixture was heated to 80°C for 2 min. The mixture was diluted with 200 fLl of mobile phase and the entire solution was transferred to an HPLC injector loop. Purification by HPLC was accomplished using column A eluted with a mobile phase of acetonitrile/water (0.1 M ammonium for mate) (25:75) at a flow of 11 ml/min (k'Ro 15-1788 = 6.6 , k'Ro 15-5528 = 3.3). The radioactive peak corresponding to the desired product was collected in a rotary evaporator and the solvent was evaporated to dryness under reduced pressure. The residue was dissolved in sterile, normal saline (7 mO and filtered through a sterile 0.22-fLm filter (Gelman Acrodisc) into a sterile, pyrogen-free evacuated vial containing sterile sodium bicarbonate solution (3 ml, 8.4%). The pH of the final solution was -7.5. Chemical and radiochemical purity and the specific activity of the formulated product were assayed by analytical HPLC (Dannals et aI. , 1990) using column B eluted with a mobile phase of acetonitrile/water (0.1 M ammonium formate) (30:70) at a flow rate of 4 mUmin (k'Ro 15-1788 = 3.3 , k'Ro 15-55 2 8 = 2.1).
Radiochemical yields of 20-30% (uncorrected) from ["C]iodomethane were obtained 17-19 min from the end of bombardment. Radiochemical purity was >99% and SAs of 1,500-3 ,600 Ci/mmol were obtained at the end of synthesis.
PET imaging
Five healthy men between the ages of 20 and 43 years were recruited by advertisement and gave informed con sent to participate in the PET study. None of the volun teers had a past history of psychiatric illness, neurological disease, or drug abuse. None was taking BZs at the time of the studies.
Each volunteer was fitted with a thermoplastic mask that was used in conjunction with x-ray computed tomog raphy (CT) to localize the planes of interest for the PET study , as previously described (Frost et aI. , 1989; Sadzot et aI. , 1991 Sadzot et aI. , , 1992 . The imaging planes were parallel to the glabellar-inion line. The most caudal plane included the inferior temporal cortex and the cerebellum, while the thalamus and midtemporal and occipital cortices were in cluded in the middle plane. The three image planes were simultaneously acquired 32 mm apart using a Neuro ECA T PET scanner, as previously described (Hoffman et aI. , 1983) . The PET data were acquired over 14 time in tervals of varying length with midpoints of 1. 5 , 3.5 , 5.5 , 10 , 13 , 16 , 22 , 28 , 34 , 40 , 46 , 56, 67 , and 84 min for a total scan time of 90 min. The images were decay and attenu ation corrected (calculated method). Region-of-interest templates were created for each plane using the summed PET image (from 10 to 30 min postinjection) and CT scan of that plane.
Each volunteer participated in paired high and low SA [I l C]flumazenil PET studies conducted -2.5 h apart on the same day. One volunteer also participated in a third PET study, which involved the administration of high SA [IIC]flumazenil after pretreatment with 0.15 mg/kg of un labeled flumazenil (inhibition study). Approximately 20 mCi of [I l C]flumazenil was administered by bolus injec tion for each study. The mean high SA was 2,346 ± 777 Ci/mmol and the mean low SA was 12.4 ± 3.6 Ci/mmoi.
Plasma and blood analyses
Plasma radioactivity concentrations were obtained from arterial blood samples and used in the determination of the time course of radioactivity, the kinetics of drug metabolism, and the free fraction of flu maze niL Time course of total radioactivity. Approximately 20 arterial blood samples were obtained during the initial 2 min of the study and 20 more samples were collected over the remainder of the 90-min time frame of the study, as described previously (Frost et aI., 1989; Sadzot et aI., 1991 Sadzot et aI., , 1992 . Samples were placed in heparinized tubes and centrifuged, and the radioactivity concentrations of the plasma aliquots were determined.
Flumazenil metabolism. Arterial blood samples were acquired prior to injection and at 5, 10, 15,45, and 90 min postinjection for the determination of radio labeled metab olites in plasma. A two-part separation process was used in this determination. The first step involved sequentially passing the plasma sample, 5 ml of H20 buffered with 0.1 N ammonium formate, and 2 ml of methanol through a C-18 reverse-phase Sep-Pak (Waters Associates). In the second step, the radioactivity in the methanol eluant was diluted with 0.1 N ammonium formate to a concentration ratio of 50% methanoll50% buffer, applied to a C-18 re verse-phase analytical HPLC column (Waters Associ ates), and eluted with a mobile phase of the same con centration ratio at a flow rate of 2 mllmin.
The extraction efficiency was evaluated at each step of the Sep-Pak separation to calculate an overall final ex traction. The preinjection blood sample, with [I l C]fluma zenil added, was used as a control to determine whether metabolites were produced in vitro and the extraction efficiency of the parent drug. Descriptions of the general procedure are available in earlier publications (Frost et aI., 1989; Sadzot et aI., 1991 Sadzot et aI., , 1992 .
Freefraction of flumazenil. Prior to injection, -5 ml of arterial blood was collected and used to evaluate the free fraction of flumazenil in plasma (f l )' [IIC]Flumazenil (-10 !-lCi) was added to a I-ml plasma sample and to a I-ml sample of 50 mM Tris buffer (pH 7.4 at room tem perature). Aliquots (0.4 ml) of these standard samples were pipetted into Centrifree micropartition systems (Amicon) and centrifuged for 20 min at 1,500 rpm in a fixed angle (35°) rotor centrifuge. The ratio of counts in the plasma ultrafiltrate to that in the plasma standard (X) and the similar ratio for the buffer (Y) were used to cal culate f l , where f l = (X/Y) * w [w = 0.94 ml water/ml plasma (Altman, 1961) ]. Previous publications of neurore ceptor binding studies have also included methods for the determination of the plasma free fraction (Perlmutter et aI., 1989; Sawada et aI., 1990; Sadzot et aI., 1991 Sadzot et aI., , 1992 ).
An additional experiment was performed to determine the adsorption of the standard samples to the plastic test tubes used in the experiments. This was examined by J Cereb Blood Flow Metab, Vol. 13, No.4, 1993 preparing several 1-ml plasma and buffer standard sam ples that were allowed to sit for 15, 25, 35, 45, and 55 min. At each of these times, the radioactivity concentrations of the standard samples were determined (total). The test tube was then emptied, washed with distilled water, and assayed for radioactivity (empty). Percentages of (empty/ total) * 100 were calculated.
Blood analyses. Blood chemistry and toxicology (alco hol, acetone, and acetaldehyde) screens were performed on whole-blood samples that were obtained from the vol unteers prior to the first injection.
The partitioning of radioactivity between the red blood cells and plasma was examined for the last two volun teers. These determinations were performed on arterial blood samples collected for each study at 5, 10, 15, 45, and 90 min postinjection.
Kinetic methods
The PET data were analyzed using a conventional three-compartment model (Fig. 1) . The intravascular space contains the unmetabolized drug in plasma (C I ) and the two extravascular brain spaces contain the free and nonspecifically bound drug (C2) and the drug specifically bound to the receptor of interest (C3).
It was assumed that only the concentrations in the brain compartments gave rise to the observed PET signal and that any contribution from the intravascular space was negligible. Therefore, the calculated model solution (CMOD) was the sum of the concentrations in the two brain compartments:
(1) Model fits to the PET data were obtained using nonlinear least-squares curve fitting (Bevington, 1969) , which uti lizes Marquardt's method of minimization (1963) .
The model equations that describe the time rate of change of the compartmental concentrations in the brain are
The kinetic parameters K 1 (mllmin/ml) and k2 (min -I) represent the bidirectional transport of drug across the blood-brain barrier, where KI is the plasma clearance.
The k3 (min -I) and k4 (min -I ) parameters reflect the rate constants for binding to and dissociation from receptors, Blood Brain Barrier (C1), which contains the unmetabolized drug in plasma, and two extravascular brain compartments, which contain the free and nonspecifica"y bound drug (C2) and drug specifi cally bound to the receptor of interest (C3). The kinetic anal ysis provides estimates of the intercompartmental transport parameters, K 1 -k4.
respectively. The first-order dissociation rate constant (koff) is assumed to be equivalent to k4• The model equations are linear or nonlinear depending on the degree of receptor occupancy. At high receptor occupancy (low SA), k3 includes the bound concentration C3(t):
(4)
This results in nonlinear model equations as shown in the expanded fo rm of Eq. 3:
where kon (nM-I min -I) is the first-order association rate constant for drug to receptor and f2 (mllml) is the fr action of drug fr ee fr om nonspecific binding in the brain (Mintun et al., 1984) . At low receptor occupancy (high SA), the bound concentration is assumed to be negligible. Equa tion 4 reduces to (6) and linear model equations result.
The linear and nonlinear pairs of equations were simul taneously fit to the high and low SA data, respectively (Huang et al., 1986 (Huang et al., , 1989 . The four equations were solved using a fo urth-order Runge-Kutta numerical inte gration method with a O.l-min step. Five kinetic param eters were estimated. The parameters K], k2' k3 (Eq. 6), and k4 were assumed to be the same for both sets of data. The fifth parameter koJ2 was determined solely fr om the low SA data (Sadzot et al., 1991 (Sadzot et al., , 1992 . The significant C3 term thus allowed k3 (Eq. 6) and koJ2 to be estimated as separate kinetic parameters (see Eq. 5).
The binding parameters Bmax (nM) and Kd (nM) are calculated ratios of the estimated kinetic parameters k3 (Eq. 6), k4' and koJ2:
The equation for Kd requires that f2 be known. This pa rameter was independently calculated for each volunteer using the fo llowing relationship (Mintun et al., 1984; Gjedde and Wong, 1990) :
An average gray matter K]lk2 ratio was obtained from linear three-compartment model fits to nine inhibition study regions. This K/k2 ratio and the subject's average f l value (from high and low SA) were used to calculate f2 ' The above equations are consistent for compartmental concentrations expressed in terms of total drug (e.g., nM). However, units of radioactivity concentration (f.1Ci/ ml) were used for the simultaneous fits. As implemented, the koJ2 parameter included the low SA (Ci/f.1mol) and the fifth kinetic parameter was actually koJ2/SA rather than koJ2 '
Model configurations. Three model configurations (Methods I-III) were examined. Method I determined the five kinetic parameters simultaneously using no a priori constraints. In Methods II and III, koJ2/SA was fixed to the product of the average value of kon obtained in recep tor-rich regions using Method I and each volunteer's mean value of f2' divided by the volunteer ' s low SA value. Method II determined fo ur parameters simulta neously. In Method III, the K l lk2 ratio was fixed to the inhibition value and only three parameters freely varied. SEs were calculated for Bmax and Kd using the partial derivatives of the rate constant estimates and the regres sion covariance matrix (Landaw and DiStefano, 1984) . Percentages of (SE/parameter estimate) * 100 were cal culated.
RESULTS
Localization of [ ll C]flumazenil
The regional localization of e IC]flumazenil was consistent with the regional rank order of eH]flu maze nil binding in vitro and with the results ob tained by other PET investigators (Persson et al., 1985 (Persson et al., , 1989b Maloteaux et al., 1988; Pappata et al., 1988; Shinotoh et al., 1989) . Images of the radioac tivity distribution, at three brain levels, for the vol unteer who was scanned three times in a single day are shown in Fig. 2 .
In Fig. 2 , the three rows of summed images were obtained after the injection of high SA, low SA, and high SA following the administration of 0. 15 mg/kg of unlabeled flumazenil, respectively. The first row shows that the distribution of [ l 1 C]flumazenil is fairly homogeneous in the cortical areas, lower in the cerebellar and inferior temporal regions, and lowest in the pons region. The middle and bottom rows display the reduction in e IC]flumazenil up take that occurs as the amount of unlabeled fluma zenil increases.
Plasma and blood analyses
Flumazenil metabolism. The Sep-Pak separation of the control samples demonstrated high extraction of the parent drug. The average final extraction de termined from the high and low SA results was 95.5 ± 3. 1 %. The HPLC results demonstrated that no drug metabolism occurred in vitro.
The final Sep-Pak extractions of the postinjection metabolite samples decreased with time. The aver age final extraction at 5 min was 84.8 ± 5.4% and at 90 min was 76.8 ± 3.2% (high and low SA data pooled). The decreased recovery of total radioac tivity was attributed to the increased proportion of the less lipophilic metabolites with time.
The HPLC separation resulted in two peaks that corresponded to unchanged flumazenil (retention time -7.5 min) and metabolites (retention time -2.2 min). The relative amounts of the two compo nents for the various time points were used in the determination of the kinetics of metabolized fluma-zenil in plasma. The HPLC data were corrected for the decreased extraction, discussed above, using the step-by-step extractions of the control and me tabolite samples.
The time course of unchanged flu maze nil was cal culated using linearly interpolated values of the ki netic curve of drug metabolism. The corrected plasma curve was obtained by multiplying the mea sured total radioactivity by the fraction of un changed flumazenil. Each subject's measured high and low SA plasma curves were corrected using the unchanged flumazenil data obtained at high and low SA, respectively, for that individual.
The kinetics of radiolabeled metabolites in plasma was fairly rapid for flumazenil. In three of the subjects, the level of metabolized flumazenil was also determined at 2 min. At this early time, an average of �98% of the radioactivity in plasma cor responded to unchanged flumazenil. However, by 5 min the average value of unchanged flumazenil was �68% and decreased to �24% at 90 min. There was no significant difference between the high and low SA kinetics of unchanged flumazenil at 5, 10, 45, and 90 min, with respective p values of 0.16, 0.35, 0.85, and 0.44 (two-sided paired t test). However, at 15 min the average low SA fraction of unchanged flumazenil (26.3 ± 2.1) was slightly less than the high SA average (33.7 ± 5.2) (p = 0. 03, two-sided paired t test).
The metabolism results in this work are in agree ment with the high SA results reported by Koeppe et al. (1991) , Frey et al. (1991) , and Debruyne et al. (1991), except for a somewhat greater metabolism in our studies at � 10 min. A curve of the pooled high and low SA results is shown in Fig. 3 . The average 2-min value reported above was included in the interpolations for each volunteer as the inclu sion of the 2-min plateau improved the fit to the observed PET data at early times.
Free fraction offlumazenil. The average value of f i determined for the high SA data was 0.50 ± 0.03 and for the low SA data it was 0.48 ± 0.05. There was no significant difference between the high and low SA results (p = 0.68, two-sided paired t test). Therefore, an average f l value was determined for each subject. There was no significant adsorption of the stan dard samples to the plastic test tubes. The maxi mum percentage adsorbed was <2% for the plasma and buffer standards, fo r the time points examined.
Blood analyses. All of the volunteers had normal electrolyte and blood chemistries. None tested pos itive for alcohol, acetone, or acetaldehyde.
The radioactivity in the blood samples progres sively partitioned in the plasma. At 5 min, the per centage of counts in the red blood cell volume was -60% of that in whole blood, and by 90 min this percentage had fallen to -30%. This partitioning suggests that the metabolites of e l C]flumazenil are in the plasma rather than in the red cell fraction.
Kinetic methods
Brainfreefraction. An average K/k2 ratio of 0. 68 ± 0.08 mUml was determined from linear three compartment model fits to nine gray matter regions of the inhibition study. This KI/k2 ratio and the sub ject ' s averagef l value resulted in a mean value off2 of 0.72 ± 0.03 mUml (Eq. 9).
Method I. Method I required the fewest assump tions but provided some problems with conver gence. As expected, the coefficients of variation (CVs) in the estimates and the SEs in Bmax and Kd were generally larger when five parameters were determined simultaneously. The results obtained using this model configuration are shown in Table 1 .
The average values of k3 do not follow the rank order of the Bmax estimates. The regional k4 esti mates are highly variable, especially in regions with lower receptor concentrations, as are the values of ko rt 2 and kon · The average value of kon and its SD increased in regions with lower receptor concentrations where convergence of the model fits was a problem and large CVs (>50%) in the individual kinetic esti mates were observed. In fact, the thalamus region could be fit for only one of the volunteers. Method I was used to obtain an estimate of kon by consid ering only those model fits that were well behaved. Fits to the occipital (n = 5), midtemporal (n = 5), and frontal (n = 4) data were used in this determi nation, for which the average calculated value of kon was 0.030 ± 0.003 oM-I min -I. The model fits to the frontal data resulted in large CV s in the kinetic estimates for one of the volunteers, and therefore this region was not included in Method II. The kort2/SA constraint applied in Method II removed the convergence difficulties, re sulted in adequate fits to thalamus data, and yielded kinetic parameters that were similar to those ob tained by Method I. Model fits (Method II) to the occipital cortex data of one of the volunteers are shown in Fig. 4 . Method II resulted in Kjlk2 ratios that ranged from 1.07 ± 0.48 in the occipital cortex to 0.61 ± 0.09 in the thalamus. Two of the volun teers had regional K/k2 ratios that were nearly twice as large as in the other volunteers, except in the thalamus region. The Bmax and Kd estimates are nearly identical to those obtained by Method I while the variability in k4 is much less ( Table 2) . Method III. The regional and intersubject vari abilities in the K/k2 ratios were addressed by spe cifically constraining Kjlk2 in Method III. The K/k2 ratio was fixed to the average inhibition value to be consistent with the fixed value of kor/2/SA. This method resulted in larger Bmax estimates especially for the occipital cortex and inferior temporal cortex and a great reduction of the parameter SDs, CVs, and SEs (Table 3) . Despite the lower variability, changes in the quality of the fits were visually ap parent in only a few cases.
Model comparison, F test. The kinetic results were examined by testing whether the additional parameter in Method II resulted in a significantly better fit to the data than Method III, using the F ratio for the additional reduction in sum of squares attributable to the extra parameter. This tested the null hypothesis that Method III is a better model. For the occipital cortex, Method II was the more satisfactory model for the two volunteers with the larger K l /k2 ratios (p < 0.01), while Method III was better for the remaining volunteers. The cerebellar results showed that Method III was more satisfac tory for four of the volunteers, while Method II was for one of the volunteers (p < 0.01). For the thala mus, Method III resulted in a significant reduction in the sum of squares for all volunteers, which is consistent with the average K l /k2 ratio (0.61 ml/ml) obtained using Method II. When the F statistic resulted in the rejection of the null hypothesis, Method III yielded binding pa rameters that were nearly a factor of 2 greater, while the difference was not as great when the null hypothesis was accepted. The percent differences (Method II versus Method III) in the occipital Bmax estimates were 44. 8 and 54.4% for the two volun teers with large K l /k2 ratios, while the average dif ference for the remaining volunteers was < 10%. Similarly, the occipital Kd estimates for the two vol unteers were 28.5 and 46.9% different, while the average difference for the others was <10%. The regional F test results are consistent with the grad ual increase in the k2 value across the occipital cor tex, cerebellum, and thalamus that is evident in the Method II results ( Table 2) .
DISCUSSION
The major finding of this work is that regional measures of BZ receptor Bmax and Kd can be ob tained from simultaneous curve fits of linear and nonlinear three-compartment models to high and low SA ["C]flumazenil PET data, respectively. Various strategies were used in the implementation of the linear and nonlinear models and an optimal method was identified. Nonspecific binding of [ ll C]flumazenil in brain was not negligible and was accounted for in the models.
Curve-fitting strategy
Sequential and simultaneous curve fittings of the linear and nonlinear models were examined. The first strategy involved sequentially fitting the linear and nonlinear three-compartment models to high and low SA ["C]flumazenil data, respectively. The high SA data were fit with the K l /k2 ratio fixed to the high SA pons (reference region) value. Next, the low SA data were fit with the K l /k2 ratio fixed to the low SA pons value and k3 fixed to the k3 (Eq. 6) value obtained at high SA. This approach resulted in convergence problems and large CVs (>50%) in the individual kinetic parameters. The second strat egy was the same as the first except that the low SA pons K/k2 ratio was used for both sets of data. Greater stability in the curve fits, but large CVs in the individual parameters, sometimes resulted when this scheme was used. The third strategy was to simultaneously fit the high and low SA data.
Curve fits were performed with the K II k2 ratio fixed to the pons value (four parameters freely varied). However, the same convergence and CV problems that were encountered with the sequential fits re suited. Finally, simultaneous fits were performed without using pons data. This approach resulted in the lowest CV s in the individual kinetic parameters and SEs in the binding parameter estimates of all strategies examined.
The first sequential method has previously been used successfully to measure human opiate recep tor binding parameters from dual SA [ ll C]diprenor phine PET data (Sadzot et al., 1991 (Sadzot et al., , 1992 ). The lack of success with the sequential fitting of the e l C]flu maze nil data is attributed largely to the use of ref erence region data. The reference region used for the [llC] diprenorphine studies was the occipital cortex, which is more optimally sampled than the pons due to its larger size. Additional measurement errors may arise in the pons data due to the rapid kinetics in that region and spillover radioactivity from adjacent vasculature.
General implementation
There are several general aspects of the quanti tative approach that affect the accuracy of the re sults. First, these studies were performed using a NeuroECAT PET scanner. The direct slice data (32 mm apart) were acquired over two time intervals only in the first 5 min and the final in-plane and axial image resolutions were only -14.0 mm. Second, the vascular contribution was assumed to be negli gible. Five percent of the total plasma concentra- tion was subtracted from the total brain concentra tion to correct for the vascular contribution. How ever, model fits to these corrected data resulted in convergence problems or kinetic parameters that were unchanged. Third, the model fits were per formed using instantaneous model solutions to ap proximate the observed PET data, which were ac cumulated over intervals of varying lengths. A small number of integrated model fits were per formed. These fits resulted in individual kinetic pa rameters that were lower in value than those ob tained using the instantaneous solutions, but Bmax and Kd estimates that were very similar (data not shown).
In spite of these limitations and approximations, the K I estimates agree with those reported by Koeppe et al. (1991) for the four-parameter model fits to high SA e I C]flumazenil PET data. In addi tion, the occipital Bmax and Kd estimates agree with the neocortical estimates obtained from the [ ll C]flu maze nil modeling study performed by Blomqvist et al. (1990) for which there was rapid PET sampling at early times (eight scans of 20 s each).
Assumptions
There are several model-specific assumptions as sociated with the kinetic methods. First, it was as sumed that K, is the same for both sets of data. The protein binding studies demonstrated that the free fraction in plasma was the same at high and low SA and the f, measurements are consistent with previ ously reported results (Roncari et aI., 1986) . These points support the simultaneous determination of K I from both sets of data.
Second, the average gray matter KJ/k2 ratio ob tained from the single inhibition study was used to determinef2 for each volunteer. The KJ/k2 ratio was estimated from the inhibition data because inaccu racies in the estimate, due to specific binding or partial volume effects, should be minimized using these data. The inhibition KJ/k2 ratio of 0.68 ± 0.08 ml/ml was similar to the ratios obtained across vol unteers in regions where receptor binding was neg ligible. The averages of the K,lk2 ratios for the low SA pons and white matter regions were 0.55 ± 0.19 and 0.68 ± 0.17 mllml, respectively. These points support the validity of using the average regional inhibition K / k2 ratio to determine f2 for each vol unteer.
The third assumption concerns the kon value used in the koJ2/SA constraint of Methods II and III. The average kon estimate obtained for receptor-rich re gions was applied to all regions. The greater reli ability of the receptor-rich kon estimate is thought to reflect its better estimation in regions with higher J Cereb Blood Flow Metab, Vol. [3, No.4, 1993 receptor binding. In going from Method I to Method II, there were no convergence difficulties, the vari ability in the regional k4 estimates was reduced, ad equate fits were obtained for all regions, the k3 es timates followed the rank order of regional binding, and the parameter estimates were in close agree ment between the methods, The binding parameters were fairly insensitive to changes in the koJ2/SA constraint as is especially evident when comparing the inferior temporal cortex results obtained by Methods I and II. The last point is consistent with the finding of Huang et al. (1989) that a 10% error in a similar constraint, kdl f2ka ' resulted in a change of <3% in the Bmax estimate.
Fourth, a regionally homogeneous free fraction was assumed when using the fixed value of koJ2/SA in Methods II and III. The variability of the inhibi tion KJ/k2 ratio was �11%, which supports the use of one value of f2 for all regions. Other factors re lated to this assumption are included in the compar ison below.
Comparison of simultaneous methods
The simultaneous F ratios (null hypothesis:
Method III is a better model) indicated that the oc cipital data of two volunteers and the cerebellar data of one volunteer were not significantly better fit when the K/k2 ratio was specifically constrained to 0.68 mllml (Method III). For all volunteers, Method III was a more satisfactory method for the thalamic data, although this was expected because the average KJ/k2 ratio determined by Method II was 0.61 mllml. The rejection of the null hypothesis resulted in binding parameters that were nearly a factor of 2 different between the two methods, while acceptance of the hypothesis resulted in a much smaller difference. The source of this differ ence was not determined. In view of these points, Method II proved to be a satisfactory method for each volunteer across all regions, while Method III was a better method for three of the five volunteers.
Methods II and III rely on a regionally uniform value off2' The average K/k2 ratios determined by Method II varied across regions ( Table 2) , which is inconsistent with a fixed value of f2' The cortical ratios were larger than those for regions with lower receptor concentrations. When regional values of f2 were calculated using the average K l /k2 ratios in Table 2 , the mean regional Kd value decreased to 8.1 ± 1.2 nM (-15% difference). The difference was greatest for the occipital cortex for which the Kd estimate went from 11.5 nM (inhibition f2 = 0.72) to 8.52 nM (occipitalf2 = 0.54).
A possible explanation for both the regional vari ability in the Method II K I I k2 ratios and the com-paratively larger Method III Bmax estimates can be found in the results of the cyclofoxy rat studies per formed by Kawai et al. (1991) . Opiate receptor binding parameters were estimated using an equi librium (bolus + constant infusion) protocol. In these studies, errors resulted from the use of refer ence region (cerebellum) nonspecific binding for all brain regions. Overestimations of Bmax and Kd for cortical regions were as large as sixfold and about twofold for the thalamus. The binding parameters were fairly well estimated for regions with nonspe cific binding that was comparable with that in the cerebellum. This explanation might support the use of Method II over Method III. However, the appli cability of the findings from equilibrium cyclofoxy rat studies to human e I C]flumazenil PET studies is uncertain. Furthermore, nonspecific binding may not be as great a factor for flumazenil as for cyclo foxy. This is plausible because nonspecific binding was found to be negligible in tracer eH]flumazenil animal studies (Goeders and Kuhar, 1985) , the in vivo measure of f2 (0.72) is large, and the regional variability in the inhibition K 1 / k2 ratios is low.
Method II was satisfactory for each volunteer across regions, but the physiological interpretation of a regionally variable f2 is unclear, particularly since the inhibition study resulted in a fairly uni form value of f2' In comparison, Method III was more often a better method, is physiologically con sistent with a uniform value of f2' and resulted in considerably lower parameter variability than Method II. The reduction in variability may be at the expense of adding bias to the parameters, but is an important factor given the small number of sub jects studied. Method III is the best simultaneous method overall due to its physiological consistency and low parameter variability.
Relation to previous models
There are a few general issues of neuroreceptor binding studies that are important to address with respect to this and previous work. One critical issue for neuroreceptor studies is the effect of receptor occupancy on the estimation of the binding param eters. As stated by Kawai et al. (1991) , large exper imental errors result in regions with high receptor concentrations when the difference between non specifically bound and receptor-bound tracer is small (plasma concentration of drug is too high).
Similarly, if the concentration of drug is too low, insufficient receptor occupancy results. In this work, receptor occupancies and volumes of distri bution were determined using the parameters ob tained by Method II. The maximal receptor occu pancy achieved at high SA was < 1 % and at low SA � 75% when averaged across the five volunteers. The volumes of distribution of free, nonspecifically bound, and receptor-bound drug were determined using Aw, fl' K I , k2' k3' and k4 in the relationships described by Sawada et al. (1990) and Koeppe et al. (1991) . In the occipital cortex, the volumes of dis tribution of free and nonspecifically bound drug were, respectively, � 6 . 5 and 10.3% of the receptor bound volume of distribution. In the cerebellum, the corresponding percentages were 12.4 and 13.0%. Accordingly, the receptor occupancies used in this work are in a range that permits accurate parameter estimation. Future studies will evaluate the effect of the high and low SA receptor occupan cies on the errors in the parameter estimates.
Another issue is the use of equilibrium and neg ligible nonspecific binding assumptions in previous analyses of e I C]flumazenil PET studies. These as sumptions were not valid for the data in this work as demonstrated by two basic results. First, true equi librium was not established following the bolus in jection of the high or low SA [ 1 I C]flumazenil. Sec ond, the kinetic results yielded an average f2 value of 0.72, which is inconsistent with an assumption of negligible nonspecific binding.
A third point concerns the use of simplified mod els to obtain measures of receptor binding. The ki netic analyses of high SA e l C]flumazenil data per formed by Koeppe et al. (1991) utilized a two compartment model to estimate total ligand distribution volumes. This is a valuable approach because the distribution volumes reflect specific binding while requiring the estimation of only two parameters from the data. In the present work, steady state was most consistently demonstrated at high SA as demonstrated by Patlak plots (Patlak and Blasberg, 1985) . However, a two-compartment model was inadequate for the low SA data. Graph ical analyses of the low SA data demonstrated that steady state did not always occur and, if so, was short-lived at variable times near the middle of the study (data not shown). The two-compartment model underestimated the low SA radioactivity concentration after 25 min by � 30% and two expo nentials were required. This is consistent with the finding of Koeppe et al. (1991) that the best two compartment model fits were obtained in regions with high receptor concentrations. The additional exponential term may be needed to account for large variations in receptor occupancy due to the increased clearance of bound radioactivity by unla beled drug.
Finally, the use of the pons as a reference region resulted in problems for all kinetic methods, and the inhibition data proved best for this work. Sawada et al . (1990) have described the determination of the free brain concentration and the K / k2 ratio using the free fraction in plasma and the tissue/plasma water partition coefficient. This approach is another example of how distribution volumes can be used effectively in place of individual parameter esti mates . This method is particularly suited for equi librium analyses because nonspecific binding in brain is not a complicating factor . The kinetic method, however, requires information about non specific binding and the estimation of f2 would still require curve fitting.
In conclusion, kinetic modeling was used to ob tain regional BZ receptor binding parameters from dual SA [llC]flumazenil PET data . This study dem onstrated that non-steady-state kinetic methods can be used to determine binding parameters for PET radiotracers with ample blood-brain barrier extrac tion and rapidly reversible binding.
